Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-Ay mice

European Journal of Pharmacology

Volumn 618, Issue 1-3, 2009, Pages 98-104

  Katsuno, Kenji ^a   Fujimori, Yoshikazu ^a   Ishikawa Takemura, Yukiko ^a   Isaji, Masayuki ^a  

^a KISSEI PHARMACEUTICAL CO LTD   (Japan)

Author keywords

KK Ay mouse; Sergliflozin etabonate; SGLT2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; SERGLIFLOZIN ETABONATE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG MECHANISM; FATTY LIVER; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; INSULIN BLOOD LEVEL; LONG TERM CARE; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ANIMALS; BENZHYDRYL COMPOUNDS; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCOSE; GLUCOSIDES; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; MICE; MICE, INBRED STRAINS; OBESITY; TIME FACTORS;

EID: 68949186346     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2009.07.001     Document Type: Article

References (39)

1. DeFronzo R.A., Simonson D., and Ferrannini E. Hepatic and peripheral insulin resistance: a common feature of type 2 (non-insulin-dependent) and type 1 (insulin-dependent) diabetes mellitus. Diabetologia 23 (1982) 313-319
2. DeFronzo R.A., Bonadonna R.C., and Ferrannini E. Pathogenesis of NIDDM. A balanced overview. Diabetes Care 15 (1992) 318-368
3. Eizirik D.L., Cardozo A.K., and Cnop M. The role for endoplasmic reticulum stress in diabetes mellitus. Endocr. Rev. 29 (2008) 42-61
4. Finegood D.T., McArthur M.D., Kojwang D., Thomas M.J., Topp B.G., Leonard T., and Buckingham R.E. β-cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes 50 (2001) 1021-1029
5. Fujimoto Y., Torres T.P., Donahue E.P., and Shiota M. Glucose toxicity is responsible for the development of impaired regulation of endogenous glucose production and hepatic glucokinase in Zucker diabetic fatty rats. Diabetes 55 (2006) 2479-2490
6. Fujimori Y., Katsuno K., Nakashima I., Ishikawa-Takemura Y., Fujikura H., and Isaji M. Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J. Pharmacol. Exp. Ther. 327 (2008) 268-276
7. Fukui Y., Masui S., Osada S., Umesono K., and Motojima K. A new thiazolidinedione, NC-2100, which is a weak PPAR-γ activator, exhibits potent antidiabetic effects and induces uncoupling protein 1 in white adipose tissue of KKAy obese mice. Diabetes 49 (2000) 759-767
8. Hermansen K., and Mortensen L.S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf. 30 (2007) 1127-1142
9. Ichikawa K., Yamato T., Ojima K., Tsuji A., Ishikawa K., Kusama H., and Kojima M. Effect of KAD-1229, a novel hypoglycaemic agent, on plasma glucose levels after meal load in type 2 diabetic rats. Clin. Exp. Pharmacol. Physiol. 29 (2002) 423-427
10. Ikeda H., Taketomi S., Sugiyama Y., Shimura Y., Sohda T., Meguro K., and Fujita T. Effects of pioglitazone on glucose and lipid metabolism in normal and insulin resistant animals. Arzneimittelforschung 40 (1990) 156-162
11. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr. Opin. Investig. Drugs 8 (2007) 285-292
12. Kahn S.E. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia 46 (2003) 3-19
13. Kahn B.B., Shulman G.I., DeFronzo R.A., Cushman S.W., and Rossetti L. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J. Clin. Invest. 87 (1991) 561-570
14. Katsuno K., Fujimori Y., Takemura Y., Hiratochi M., Itoh F., Komatsu Y., Fujikura H., and Isaji M. Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J. Pharmacol. Exp. Ther. 320 (2007) 323-330
15. Kees K.L., Fitzgerald J.J., Steiner K.E., Mattes J.F., Mihan B., Tosi T., Mondoro D., and McCaleb M.L. New potent antihyperglycemic agents in db/db mice: synthesis and structure-activity relationship studies of (4-substituted benzyl) (trifluoromethyl)pyrazoles and -pyrazolones. J. Med. Chem. 39 (1996) 3920-3928
16. Li Y., Wang Z., Furukawa N., Escaron P., Weiszmann J., Lee G., Lindstrom M., Liu J., Liu X., Xu H., Plotnikova O., Prasad V., Walker N., Learned R.M., and Chen J.L. T2384, a novel antidiabetic agent with unique peroxisome proliferator-activated receptor γ binding properties. J. Biol. Chem. 283 (2008) 9168-9176
17. Link J.T., and Sorensen B.K. A method for preparing C-glycosides related to phlorizin. Tetrahedron Lett. 41 (2000) 9213-9217
18. Marchesini G., Brizi M., Bianchi G., Tomassetti S., Bugianesi E., Lenzi M., McCullough A.J., Natale S., Forlani G., and Melchionda N. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 50 (2001) 1844-1850
19. McGarry J.D. What if Minkowski had been ageusic? An alternative angle on diabetes. Science 258 (1992) 766-770
20. Meng W., Ellsworth B.A., Nirschl A.A., McCann P.J., Patel M., Girotra R.N., Wu G., Sher P.M., Morrison E.P., Biller S.A., Zahler R., Deshpande P.P., Pullockaran A., Hagan D.L., Morgan N., Taylor J.R., Obermeier M.T., Humphreys W.G., Khanna A., Discenza L., Robertson J.G., Wang A., Han S., Wetterau J.R., Janovitz E.B., Flint O.P., Whaley J.M., and Washburn W.N. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 51 (2008) 1145-1149
21. Mevorach M., Giacca A., Aharon Y., Hawkins M., Shamoon H., and Rossetti L. Regulation of endogenous glucose production by glucose per se is impaired in type 2 diabetes mellitus. J. Clin. Invest. 15 (1998) 744-753
22. + glucose cotransporter (SGLT) inhibitors. Bioorg. Med. Chem. Lett. 13 (2003) 2269-2272
23. +-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 48 (1999) 1794-1800
24. +-glucose cotransporter, in neonatally streptozotocin-treated rats. Eur. J. Pharmacol. 391 (2000) 183-192
25. Roberts C.K., and Barnard R.J. Effects of exercise and diet on chronic disease. J. Appl. Physiol. 98 (2005) 3-30
26. Robertson R.P., Harmon J., Tran P.O., Tanaka Y., and Takahashi H. Glucose toxicity in β-cells: type 2 diabetes, good radicals gone bad, and the glutathione connection. Diabetes 52 (2003) 581-587
27. Rossetti L., Shulman G.I., Zawalich W., and DeFronzo R.A. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J. Clin. Invest. 80 (1987) 1037-1044
28. Savage D.B., Petersen K.F., and Shulman G.I. Disordered lipid metabolism and the pathogenesis of insulin resistance. Physiol. Rev. 87 (2007) 507-520
29. Scheen A.J., and Lefebvre P.J. Antiobesity pharmacotherapy in the management of type 2 diabetes. Diabetes Metab. Res. Rev. 16 (2000) 114-124
30. +-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4′-dehydroxyphlorizin derivatives substituted on the B ring. J. Med. Chem. 42 (1999) 5311-5324
31. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
32. Utzschneider K.M., and Kahn S.E. The role of insulin resistance in nonalcoholic fatty liver disease. J. Clin. Endocrinol. Metab. 91 (2006) 4753-4761
33. Wajchenberg B.L. β-cell failure in diabetes and preservation by clinical treatment. Endocr. Rev. 28 (2007) 187-218
34. Wallace T.M., and Matthews D.R. Poor glycaemic control in type 2 diabetes: a conspiracy of disease, suboptimal therapy and attitude. QJM 93 (2000) 369-374
35. Weinstock R.S., Murray F.T., Diani A., Sangani G.A., Wachowski M.B., and Messina J.L. Pioglitazone: in vitro effects on rat hepatoma cells and in vivo liver hypertrophy in KKAy mice. Pharmacology 54 (1997) 169-178
36. Wilding J. Thiazolidinediones, insulin resistance and obesity: finding a balance. Int. J. Clin. Pract. 60 (2006) 1272-1280
37. Wood I.S., and Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br. J. Nutr. 89 (2003) 3-9
38. +-glucose cotransporters. Am. J. Physiol. Renal Physiol. 280 (2001) F10-F18
39. Zhang X., Urbanski M., Patel M., Zeck R.E., Cox G.G., Bian H., Conway B.R., Pat, Beavers M., Rybczynski P.J., and Demarest K.T. Heteroaryl-O-glucosides as novel sodium glucose co-transporter 2 inhibitors. Part 1. Bioorg. Med. Chem. Lett. 15 (2005) 5202-5206